Diabetes Prevalence in Urban India Soars With a 30 Percent Increase in …

LONDON, Sep 19, 2011 (BUSINESS WIRE) —
The prevalence of diabetes in urban India is accelerating at a rapid
rate and now stands at 5.5 percent (just under 20 million people),
compared with 4.6 percent in 2007 — equivalent to a 30 percent increase
in actual population numbers over the last four years — according to new
research by GfK HealthCare’s Roper Global Diabetes Group. Moreover,
a full 10 percent of these patients have been diagnosed in the past 12
months.

According to GfK HealthCare’s 2011 Roper Global Diabetes Patient
Study for India, insulin use has also made steady gains in India
over the past decade — trending at almost a 50 percent increase — with
current rates at 23 percent, up from 16 percent in 2001. Patients in
India, more so than other emerging markets, depend to a high degree on a
third party for administration of insulin (friend, relative or health
care provider). Although 57 percent of patients self-inject, the
remainder are injected either by a friend or relative (24 percent) or
their health care provider (19 percent).

In the non-insulin sector, the use of oral medication (OAA) has remained
at around 80 percent of diabetes patients in India over the last four
years. Of note, although the Indian market has traditionally been
comprised of patients on OAA monotherapy, 2011 figures show nearly 60
percent are on combination therapy, up significantly from the 2001
figures of 35 percent.

Also setting India apart from other diabetes markets is the low rate of
blood glucose self-testing (includes testing by relatives/friends),
where only 21 percent of patients self-test, a figure which is flat
against 2007 rates though up from 2001, when self-testing rates were
just 7 percent. More commonly, more than half of diabetes patients in
India delegate the responsibility for blood glucose testing to their
health care professional.

Another indicator of the infancy of the self-testing market in India is
the low frequency of testing; an average of just 14 tests per month are
claimed by self-testers, compared with a recommendation by health care
providers of 38 tests per month. It is worth noting that cost may be a
limiting factor to testing, as compared to the more developed markets;
almost all patients in India have to pay for their testing meters and
strips.

646 Diabetes Patients Share Their Insights

Reflecting insights from 646 diabetes patients in India, fielded via
in-depth face-to-face interviews in the last quarter of 2010, GfK
HealthCare’s Roper Global Diabetes Group’s 2011 Patient Study for
India provides comprehensive perspectives of the country’s diabetes
market. The study offers comparable data back to 1996, across diabetes
markets in 25 total countries.

About GfK HealthCare

GfK HealthCare (
www.gfkhc.com )
is the largest provider of fully integrated custom health care marketing
research in the world. With the broadest range of custom and syndicated
research offerings as well as innovative proprietary approaches to meet
a product’s needs across its life cycle. GfK HealthCare is part of the
Custom Research sector within the GfK Group (
www.gfk.com ),
which offers the fundamental knowledge that industry, retailers,
services companies and the media need to make market decisions. GfK
delivers a comprehensive range of information and consultancy services
in the three business sectors of Custom Research, Retail and Technology
and Media. The No. 4 market research organization worldwide operates in
more than 100 countries and employs over 11,000 staff. In 2010, the GfK
Group’s sales amounted to EUR 1.29 billion.

SOURCE: GfK HealthCare




        GfK HealthCare
        Jessica Makovsky
        VP Global Communications
        1-267-304-3780
        jessica.makovsky@gfk.com



Copyright Business Wire 2011

Comtex